




A




B




C




D




E



F



G



Supplementary Figure S8. MSH2 depletion suppresses MMC sensitivity in BRCA1-deficient cells, but not FANCA-deficient cells

(A) Graph shows the percentage of viable MCF7 cells 5 days after indicated dose of MMC and indicated siRNAs (immunoblot shown in Figure 6A).

(B) Immunoblot analysis shows BRCA1 and MSH2 expression in MCF7 cells treated with indicated siRNAs. (C) Graph shows the percentage of viable cells 5 days after indicated dose of MMC.

(D) Immunoblot analysis of FANCA and MSH2 expression in U2OS cells treated with indicated siRNAs.

(E) Graph shows the percentage of viable cells 5 days after indicated dose of MMC. (F) Immunoblot analysis of FANCA and MSH2 expression in FA-A (PD6914) cells stably expressing vectors (V) or FANCA that were also transfected with siRNAs to MSH2 or control. (G) Graph shows the percentage of viable cells 5 days after MMC. Where shown, error bars represent standard deviations from three independent experiments.